Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile

• US 20070037192A1
• Filed: 07/25/2006
• Published: 02/15/2007
• Est. Priority Date: 07/25/2005
• Status: Abandoned Application

• Current Assignee: GTC Biotherapeutics, Inc.
• Original Assignee: GTC Biotherapeutics, Inc.
• Inventors: Hendry, Christopher, Ziomek, Carol
• Application Number:
  US11/493,124
• Publication Number:
  US 20070037192A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 1/30 by precipitation
• CPC Class Codes: C07K 1/36 by a combination of two or more processes of different types
• CPC Class Codes: C07K 14/8128 Antithrombin III

Abstract

Methods of purifying antithrombin from a variety of source materials including from the milk of transgenic mammals to enhance its safety profile vis-à-vis the removal and/or the inactivation of contaminants. Contaminants would include particulate matter, viruses, and/or prions.

Claims

1. A method for purifying a molecular species of interest from a feedstream, comprising:

(a) Filtering said feedstream by a tangential-flow filtration process (TFF) to produce a TFF permeate;

(b) Cycling said TFF permeate through a closed loop system until at least 50% of the said molecular species of interest is captured wherein said closed loop system further comprises a Heparin-affinity column;

(c) Nanofiltering said TFF/heparin eluate viral removal such that potential viral adventitious agents are removed;

(d) Removing unwanted molecular contaminants through the use of an anion exchange column;

(e) Utilizing a hydrophobic interaction column to eliminate unwanted or variant forms of said molecular species of interest; and

,

(f) formulating said molecular species;

(g) lyophilizing said molecular species; and

,

(h) Heating the purified lyophilized molecular species of interest to inactive viruses.

2. The method of claim 1, further comprising lyophilizing said molecular species of interest after eluting this product from said hydrophobic interaction column.

3. The method of claim 1, wherein said heating further comprises a virus inactivation step providing dry heat of 80°

C. for at least 72 hours.

4. The method of claim 1, wherein said heparin affinity column is a Heparin-Hyper D column.

5. The method of claim 1, wherein said TFF permeate is cycled through a closed loop system until at least 60% of said molecular species of interest is captured from a feedstream.

6. The method of claim 1, wherein said TFF permeate is cycled through a closed loop system until at least 90% of said molecular species of interest is captured from a feedstream.

7. The method of claim 1, wherein said TFF permeate is cycled through a closed loop system for at least 5 volume cycles.

8. The method of claim 1, wherein said TFF permeate is cycled through a closed loop system for at least 8 volume cycles.

9. The method of claim 1, wherein after said TFF permeate is cycled through said heparin affinity column the retentate molecular species of interest is washed and then eluted with a first buffer.

10. The method of claim 9, wherein said first buffer is a salt buffer further comprising a sodium chloride buffer.

11. The method of claim 10, wherein said salt buffer is 2.5 M sodium chloride

12. The method of claim 1, wherein said anion column is a sepharose column.

13. The method of claim 12, wherein said sepharose column is a ANX-Sepharose column.

14. The method of claim 13, wherein after the use of said ANX-Sepharose column said molecular species of interest is eluted from said ANX-Sepharose column with a second buffer.

15. The method of claim 14, wherein said second buffer is 0.32 M sodium chloride.

16. The method of claim 1, wherein after said anion exchange column a product eluate is collected and conditioned with sodium citrate.

17. The method of claim 16, wherein said conditioned product eluate is applied to a Methyl HyperD column and eluted with a third buffer.

18. The method of claim 17, wherein said third buffer is a sodium citrate buffer.

19. The method of claim 1, wherein the final formulation of the said conditioned product eluate is achieved by concentration and diafiltration into a citrate, glycine, sodium chloride buffer.

20. The method of claim 19, wherein the final protein concentration of the composition ranges from 20 IU/ml to 200 IU/ml.

21. The method of claim 1, wherein said heat treatment further comprises heat treating lyophilized molecular species of interest at 80°

C. for 72 hours in a viral inactivation step.

22. The method of claim 1, wherein during said tangential flow filtration process the flux is maintained at a level ranging from about 5 to 100% of transition point flux in the pressure-dependent region of the flux versus TMP curve.

23. The method of claim 22, wherein transmembrane pressure is held substantially constant along the membrane at a level no greater than the transmembrane pressure at the transition point of the filtration, whereby said molecular species of interest is selectively separated from said feedstream such that said molecular species of interest retains its biological activity.

24. The method of claim 1, wherein said tangential-flow filtration process through a filtration membrane having a pore size that separates said molecular species of interest from said feedstream.

25. The method of claim 24, wherein said filtration membrane has a pore size of between 200 and 700 kD.

26. The method of claim 25, wherein said filtration membrane has a pore size of 500 kD.

27. The method of claim 26, wherein said filtration membrane is a 500 kD hollow fiber membrane.

28. The method of claim 1, wherein prior to entering the purification process the feedstream is diluted with an equal volume of an EDTA buffer.

29. The method of claim 1, wherein said molecular species of interest is an antithrombin protein.

30. The method of claim 1, wherein said purity of said molecular species of interest was at least 90%.

31. The method of claim 1, wherein said purity of said molecular species of interest was greater than 99%.

32. The method of claim 1, wherein said physiological activity of said molecular species of interest was at least 90%.

33. The method of claim 1, wherein said physiological activity of said molecular species of interest was greater than 99%.

34. The method of claim 1, wherein the purity of said molecular species is determined by SDS-PAGE.

35. The method of claim 1, wherein the purity of said molecular species is determined by reverse phase-HPLC.

36. The method of claim 29, wherein said molecular species of interest is a recombinant antithrombin protein.

37. The method of claim 36, wherein said molecular species of interest is a transgenically produced recombinant antithrombin protein.

38. The method of claim 1, wherein all filtration stages are ultrafiltrations.

39. The method of claim 1, wherein said feedstream is milk

40. The method of claim 1, wherein said feedstream is a cell lysate solution.

41. The method of claim 1, wherein said molecular species of interest is a biopharmaceutical.

42. The method of claim 39, wherein the condition of said milk is selected from one of the following states:

a) raw;

b) diluted;

c) treated with a buffer solution;

d) chemically treated; and

e) partially evaporated.

43. The method of claim 1, wherein said fractionation step utilizes ceramic filtration membranes.

44. The method of claim 1, wherein said clarification step utilizes ceramic filtration membranes.

45. The method of claim 1, wherein said fractionation step utilizes polymeric filtration membranes.

46. The method of claim 1, wherein said clarification step utilizes polymeric filtration membranes.

47. The method of claim 1, wherein said fractionation step utilizes cellulose filtration membranes.

48. The method of claim 1, wherein said clarification step utilizes cellulose filtration membranes.

49. The method of claim 1, further comprising optimizing systematic parameters.

50. The method of claim 49, wherein said systematic parameters include temperature, feedstream flow velocity, transmembrane pressure, feedstream concentration and diafiltration volume.

51. The method of claim 50, further comprising optimizing systematic parameters for the production of recombinant human antithrombin.

52. The method of claim 1, wherein said molecular species of interest are biological entities selected from the group consisting of proteins, polypeptides, peptides and glycoproteins,

53. The method of claim 1, wherein the optimal temperature range is from 15°

C. to 50°

C.

54. The method of claim 1, wherein the optimal temperature range is from 20°

C. to 35°

C.

55. The method of claim 1, wherein the optimal temperature range is from 25°

C. to 29°

C.

56. The method of claim 1, wherein the feedstream flow velocity is from 10 cm/sec to 100 cm/sec.

57. The method of claim 1, wherein the feedstream flow velocity is from 20 cm/sec to 60 cm/sec.

58. The method of claim 1, wherein the feedstream flow velocity is from 25 cm/sec to 45 cm/sec.

59. The method of claim 1, wherein the transmembrane pressure ranges from 2 psi to 40 psi.

60. The method of claim 1, wherein the transmembrane pressure ranges from 5 psi to 30 psi.

61. The method of claim 1, wherein the transmembrane pressure ranges from 10 psi to 20 psi.

62. The method of claim 39, wherein the feedstream concentration is from 0.25×

to 4×

natural milk.

63. The method of claim 39, wherein the feedstream concentration is from 0.5×

to 3×

natural milk.

64. The method of claim 39, wherein the feedstream concentration is from 1.0×

to 2×

natural milk.

65. The method of claim 1, wherein the diafiltration volume range is from 1×

to 20×

the volume of concentrated retentate.

66. The method of claim 1, wherein the diafiltration volume range is from 3×

to 15×

the volume of concentrated retentate.

67. The method of claim 1, wherein the diafiltration volume range is from 5×

to 10×

the volume of concentrated retentate.

68. The method of claim 39, wherein said milk is treated with a solution selected from the group consisting of:

a) water;

b) a buffered aqueous salt solution;

c) chelating agent;

d) acid solution; and

e) alkali solution.

69. The method of claim 1, further comprising filtering the filtrate from the filtration in a second tangential-flow filtration stage through a membrane having a smaller pore size than the membrane used in the first filtration stage, and recycling the filtrate of this second filtration stages back to the first filtration stage, whereby the process is repeated.

70. A pharmaceutical composition according to the method of claim 1, wherein the reconstitution media is selected from any one of polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polysorbate 81, polysorbate 85, polysorbate 120;

and, human albumin.

71. A pharmaceutical composition according to claim 70, wherein the reconstitution media is polysorbate 80.

72. A pharmaceutical composition according to claim 70, wherein the reconstitution media is human albumin.

77. The molecular species of interest produced by the process of claim 1.

78. The molecular species of claim 77, wherein said molecular species of interest is used therapeutically.

79. The therapeutic conditions of claim 78, wherein the therapeutic condition treated is selected from the group consisting of:

a hereditary rhAT deficiency;

DIC, burns, heparin resistance, neurocognitive deficit due to CABG surgery; and

, sepsis.

80. The process of claim 1, wherein the resultant purified molecular species of interest is more than 90% from prion contamination found in normal milk.

81. The process of claim 1, wherein the resultant purified molecular species of interest is more than 90% from prion contamination found in transgenic milk.

82. The process of claim 1, wherein the resultant purified molecular species of interest is more than 90% from viral contamination found in normal milk.

83. The process of claim 1, wherein the resultant purified molecular species of interest is more than 90% from viral contamination found in transgenic milk.

73. A method of purifying a recombinant antithrombin III (rhAT) or a fragment thereof from a feedstream, comprising:

Solubilizing said rhAT from a feedstream utilizing a tangential flow filtration process;

Washing said filtrate on a membrane with a PBS solution wherein said rhAT or fragment thereof remains in the retentate on the purification column;

Adding an aqueous solution to said rhAT remaining in the retentate to solubilize it;

Eluting said rhAT from said purification column; and

,

Purifying out said rhAT from elution.

74. A method for purifying a molecular species of interest from a feedstream, comprising:

a) Filtering said feedstream by a tangential-flow filtration process (TFF) to produce a TFF permeate;

b) Cycling said TFF permeate to through a closed loop system until at least 50% of the said molecular species of interest is captured wherein said closed loop system further comprises a Heparin-affinity column;

c) Collecting a first eluate from said Heparin-affinity column and processing said first eluate through a first concentration step and a first diafiltration step;

d) Transferring said first eluate into a downstream processing and formulation area thereafter again transferring said first eluate after said first concentration step and said first diafiltration step to a ion exchange chromatography column to generate a second eluate;

e) Removing unwanted molecular contaminants through the use of an anion exchange column;

f) Processing said second eluate through an anionic exchange chromatography column;

g) Nanofiltering said TFF permeate ion step for viral removal such that potential adventitious agents are removed;

h) Processing said second eluate through a second concentration step and a second diafiltration step to generate a third eluate;

i) Transferring said product eluate through a nanofilter capable of removing viruses from said third eluate;

j) Utilizing a hydrophobic interaction column to eliminate unwanted or variant forms of said molecular species of interest;

k) Processing said product eluate through a third concentration step and a third diafiltration step to generate a product eluate;

l) Loading said product eluate on a anion column and thereafter eluting with a buffer; and

,

m) Heating the purified molecular species of interest to inactive viruses.

75. The process of claim 74, wherein said molecular species of interest is rhAT.

76. The molecular species of interest produced by the process of claim 74.